Related Experiment Video

Updated: Oct 17, 2025

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

8.4K

Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe

Guoxin Zhang1, Zhen Dong1, Ryan C Gimple1,2

  • 1Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA.

The Journal of Experimental Medicine
|October 7, 2021
PubMed

Insights

Researchers identified EYA2 as a key target in glioblastoma stem cells (GSCs). Inhibiting EYA2

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Glioblastoma is a highly lethal brain cancer.
  • Glioblastoma stem cells (GSCs) drive tumor growth and recurrence.
  • Identifying novel therapeutic targets in GSCs is crucial.

Purpose of the Study:

  • To identify novel therapeutic targets in glioblastoma stem cells (GSCs).
  • To investigate the role of EYA2 in GSC maintenance and survival.

Main Methods:

  • Comparative gene expression profiling of GSCs, differentiated glioblastoma cells (DGCs), and neural stem cells (NSCs).
  • Functional assays to assess the impact of EYA2 targeting on GSC properties.
  • Analysis of EYA2 localization and phosphatase activity in GSCs.
  • In vitro and in vivo studies using genetic and pharmacological inhibition of EYA2.

Main Results:

  • EYA2 was preferentially expressed in GSCs compared to DGCs and NSCs.
  • Targeting EYA2 impaired GSC maintenance, self-renewal, and induced apoptosis and cell cycle arrest.
  • EYA2 localized to centrosomes in GSCs and its tyrosine phosphatase activity was essential for mitotic spindle assembly and GSC survival.
  • Inhibition of EYA2 phosphatase activity in vitro and in vivo extended survival in tumor-bearing mice.
  • High EYA2 expression correlated with poor glioblastoma patient prognosis.

Conclusions:

  • EYA2 phosphatase activity is critical for glioblastoma stem cell growth and survival.
  • EYA2 represents a promising therapeutic target for glioblastoma.
  • EYA2 inhibitors may offer a high therapeutic index for treating glioblastoma.

More Related Videos

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.3K
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

16.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K